BioNano Genomics Inc vs Elastic NV — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Elastic NV trades at $62.75 (market cap $6.48B). The key difference: Elastic NV is far larger — about 490.9× BioNano Genomics Inc's market cap, and Elastic NV is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | ESTC | |
|---|---|---|
Market Cap | $13.20M | $6.48B |
Sector | Health | Technology |
52-Week High | $4.92 | $94.47 |
52-Week Low | $1.09 | $43.30 |
Enterprise Value | $15.81M | $5.70B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Elastic N.V. (ESTC) trades at $62.43, up 3.64% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and projected revenue growth from $1.48B to $1.7B. Technical indicators signal bullish momentum, though RSI suggests potential overbought conditions near-term.
ESTC presents a compelling growth opportunity with 67.65% analyst buy ratings and a $72.80 consensus target, offering 16.6% upside. Key risks include ongoing legal investigations and the transition to profitability after 2025's net loss. The company's leadership in SIEM and AI capabilities supports long-term growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →